• $1.2B
    Market Cap
  • N/A
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
N/A
N/A
Cost of Revenue
N/A
N/A
Gross Profit
0
N/A
Sales and Marketing Expense
N/A
N/A
Research and Development Expense
-138.3M
N/A
Depreciation and Amortization Expense
578,000
N/A
Total Operating Expenses
169.1M
N/A
Operating Profit
-169.1M
N/A
Interest Income
5.5M
N/A
Interest Expense
N/A
N/A
Interest Income and Expense and Net
5.5M
N/A
Total Nonoperating Income and Expense
7.9M
N/A
Income before Taxes
-169.1M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-161.2M
N/A
Net Income from Continuing Operations Applicable to Common
-161.2M
N/A
Basic EPS and Net Income
-18.56
N/A
Diluted EPS and Net Income
-18.56
N/A
Basic Weighted Average Shares
8.7M
N/A
Diluted Weighted Average Shares
8.7M
N/A
Balance Sheet
Cash and Cash Equivalents
46.7M
N/A
Short-Term Investments
258.4M
N/A
Cash and Cash Equivalents and Short-Term Investments
305.1M
N/A
Total Current Assets
324.7M
N/A
Accumulated Depreciation
2.6M
N/A
Property and Plant and Equipment and Net
1.1M
N/A
Total Long-Term Assets
59,000
N/A
Total Assets
479.5M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
N/A
N/A
Total Current Liabilities
16.2M
N/A
Total Long-Term Debt
N/A
N/A
Total Long-Term Liabilities
4.9M
N/A
Total Liabilities
21.1M
N/A
Retained Earnings
-360.5M
N/A
Total Stockholders Equity
458.4M
N/A
Total Shares Outstanding
44.0M
N/A
Cash Flow
Cash from Operating Activities
-138.1M
N/A
Capital Expenditures
473,000
N/A
Cash from Investing Activities
-323.2M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
469.8M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow